| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/15/2012 | CA2746087A1 Use of preventing and treating inflammation |
| 01/12/2012 | WO2012006619A2 ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS |
| 01/12/2012 | WO2012006612A2 Use of trans-palmitoleate in identifying and treating metabolic disease |
| 01/12/2012 | WO2012006600A1 Method and composition for the treatment of tumors |
| 01/12/2012 | WO2012006589A2 Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| 01/12/2012 | WO2012006584A2 Therapeutic regimens for hedgehog-associated cancers |
| 01/12/2012 | WO2012006563A2 Novel daidzein analogs as treatment for cancer |
| 01/12/2012 | WO2012006552A1 Combinations of kinase inhibitors for the treatment of cancer |
| 01/12/2012 | WO2012006551A2 Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| 01/12/2012 | WO2012006550A2 Methods and compositions for treatment of lipogenic virus related conditions |
| 01/12/2012 | WO2012006544A1 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| 01/12/2012 | WO2012006525A2 Pkc activators and anticoagulant in regimen for treating stroke |
| 01/12/2012 | WO2012006516A2 Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke |
| 01/12/2012 | WO2012006510A1 Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke |
| 01/12/2012 | WO2012006506A1 Metabolic gene, enzyme, and flux targets for cancer therapy |
| 01/12/2012 | WO2012006477A1 Compounds and methods for inhibiting phosphate transport |
| 01/12/2012 | WO2012006473A1 Compounds and methods for inhibiting phosphate transport |
| 01/12/2012 | WO2012006419A2 Pro-neurogenic compounds |
| 01/12/2012 | WO2012006398A2 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
| 01/12/2012 | WO2012006397A2 Antiperspirant products comprising natural phospholipids and methods for manufacturing the same |
| 01/12/2012 | WO2012006321A2 Novel antibacterial compounds, methods of making them, and uses thereof |
| 01/12/2012 | WO2012006315A2 Methods of immune modulation |
| 01/12/2012 | WO2012006273A1 Combination therapies with cox-2 inhibitors and treprostinil |
| 01/12/2012 | WO2012006205A1 Crystalline form of a 3-phenoxymethylpyrrolidine compound |
| 01/12/2012 | WO2012006203A1 N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors |
| 01/12/2012 | WO2012006202A1 Rho kinase inhibitors |
| 01/12/2012 | WO2012006178A1 Salvinorin compositions and uses thereof |
| 01/12/2012 | WO2012006154A1 Pharmaceutical compositions containing vanoxerine |
| 01/12/2012 | WO2012006117A2 Reduction of microglia-mediated neurotoxicity by kca3.1 inhibition |
| 01/12/2012 | WO2012006104A2 Compounds and methods for treating tuberculosis infection |
| 01/12/2012 | WO2012006083A2 Targeted receptor-mediated sirna |
| 01/12/2012 | WO2012006070A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/12/2012 | WO2012006065A1 Resveratrol-containing compositions and methods of use |
| 01/12/2012 | WO2012006060A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/12/2012 | WO2012006055A2 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/12/2012 | WO2012006032A2 Treatment of blood cancer |
| 01/12/2012 | WO2012006014A2 Multi-component pharmaceuticals for treating diabetes |
| 01/12/2012 | WO2012006012A1 Method for dosing an oral solution |
| 01/12/2012 | WO2012006004A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | WO2012006003A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | WO2012005973A1 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| 01/12/2012 | WO2012005885A2 Nutraceutical product containing anatabine and yerba maté |
| 01/12/2012 | WO2012005805A1 Azaindazoles |
| 01/12/2012 | WO2012005795A1 Process for the synthesis of substituted morphinans |
| 01/12/2012 | WO2012005745A2 Compositions and methods for the inhibition of muscle contraction |
| 01/12/2012 | WO2012005605A1 A combination composition comprising ibuprofen and paracetamol |
| 01/12/2012 | WO2012005582A1 Nutritional composition for the stimulation of muscle protein synthesis |
| 01/12/2012 | WO2012005581A1 Xanthanodien for the treatment of cancer |
| 01/12/2012 | WO2012005572A1 Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| 01/12/2012 | WO2012005568A1 Nutritional composition for the stimulation of muscle protein synthesis |
| 01/12/2012 | WO2012005536A2 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound |
| 01/12/2012 | WO2012005500A2 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration |
| 01/12/2012 | WO2012005365A1 Particle coating preparation |
| 01/12/2012 | WO2012005343A1 Substituted pyridine compound |
| 01/12/2012 | WO2012005339A1 Prophylactic or therapeutic agent for diabetes |
| 01/12/2012 | WO2012005311A1 Composition for contact lens care |
| 01/12/2012 | WO2012005299A1 Ros tyrosine kinase inhibitor |
| 01/12/2012 | WO2012005229A1 N-hydroxyformamide derivative and pharmaceutical containing same |
| 01/12/2012 | WO2012005227A1 Tetrahydrocarboline derivative |
| 01/12/2012 | WO2012004917A1 Neurite outgrowth agent |
| 01/12/2012 | WO2012004900A1 Thienopyrimidine compounds |
| 01/12/2012 | WO2012004875A1 Novel substance separated from orchidaceous plant, and extract, antioxidant, antibacterial agent, anticancer agent and antiinflammatory agent containing same |
| 01/12/2012 | WO2012004801A1 Process for imatinib mesylate |
| 01/12/2012 | WO2012004800A1 Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions |
| 01/12/2012 | WO2012004799A1 Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof |
| 01/12/2012 | WO2012004768A1 Propofol for use as an antiviral medicament |
| 01/12/2012 | WO2012004748A1 Novel quinoline esters useful for treating skin disorders |
| 01/12/2012 | WO2012004743A1 Benzenesulfonamides useful as sodium channel inhibitors |
| 01/12/2012 | WO2012004732A1 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof |
| 01/12/2012 | WO2012004731A1 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |
| 01/12/2012 | WO2012004726A1 Trans-epithelial osmotic collyrium for the treatment of keratoconus |
| 01/12/2012 | WO2012004722A1 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| 01/12/2012 | WO2012004714A2 Chemical compounds |
| 01/12/2012 | WO2012004706A2 Chemical compounds |
| 01/12/2012 | WO2012004698A1 Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| 01/12/2012 | WO2012004691A2 Pharmaceutical formulations of rasagiline |
| 01/12/2012 | WO2012004677A1 Solid state forms of etoricoxib salts |
| 01/12/2012 | WO2012004669A1 Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster |
| 01/12/2012 | WO2012004653A1 Method for inhibition of nf-kb gene expression |
| 01/12/2012 | WO2012004604A1 Tetrazole compounds as calcium channel blockers |
| 01/12/2012 | WO2012004585A1 Ingestible formulation comprising glycomacropeptide and at least one of tryptophan, tyrosine and phenylalanine and uses thereof |
| 01/12/2012 | WO2012004549A1 Phenoxypropanol derivatives and their use in treating cardiac and cardiovascular diseases |
| 01/12/2012 | WO2012004443A1 Phenyl methyl sulfones with anti-inflammatory activity and anti-tumour activity |
| 01/12/2012 | WO2012004438A1 Injectable pharmaceutical formulation of melphalan |
| 01/12/2012 | WO2012004410A1 B7-h3 antagonists and taxanes |
| 01/12/2012 | WO2012004400A1 Novel spiroheterocyclic compounds as mglu5 antagonists |
| 01/12/2012 | WO2012004390A1 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders |
| 01/12/2012 | WO2012004378A1 Spiro-cyclic amine derivatives as s1p modulators |
| 01/12/2012 | WO2012004375A1 Bisaryl (thio)morpholine derivatives as s1p modulators |
| 01/12/2012 | WO2012004373A1 Fused heterocyclic derivatives as s1p modulators |
| 01/12/2012 | WO2012004330A1 Nos-inhibitor l-nil for use in chronic pulmonary diseases |
| 01/12/2012 | WO2012004324A1 New drug combinations for the treatment of malaria |
| 01/12/2012 | WO2012004299A1 Tetrahydro-pyrido-pyrimidine derivatives |
| 01/12/2012 | WO2012004291A1 Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients. |
| 01/12/2012 | WO2012004287A1 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors |
| 01/12/2012 | WO2012004270A1 Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
| 01/12/2012 | WO2012004269A1 (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
| 01/12/2012 | WO2012004264A1 Solifenacin salts |
| 01/12/2012 | WO2012004259A1 Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases |
| 01/12/2012 | WO2012004258A1 Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |